| Symbol | OTLK |
|---|---|
| Name | OUTLOOK THERAPEUTICS, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Address | 4260 U.S. ROUTE 1,SUITE 320, MONMOUTH JUNCTION, New Jersey, 08852, United States |
| Telephone | +1 609 619-3990 |
| Fax | — |
| — | |
| Website | https://www.outlooktherapeutics.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001649989 |
| Description | Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. Additional info from NASDAQ: |
Director Jahr Robert Charles 🟢 acquired 303.0K shares (1 derivative) of Outlook Therapeutics, Inc. (OTLK) at $1.10 Transaction Date: Aug 14, 2026 | Filing ID: 097406
Read moreSukhtian Ghiath M. 🟢 acquired 5.1M shares (1 derivative) of Outlook Therapeutics, Inc. (OTLK) at $1.10 ($5.3M) Transaction Date: Aug 12, 2026 | Filing ID: 000894
Read moreDirector KENYON LAWRENCE A 🟢 acquired 202.0K shares (1 derivative) of Outlook Therapeutics, Inc. (OTLK) at $1.10 Transaction Date: Aug 14, 2026 | Filing ID: 000009
Read moreNew Form SCHEDULE 13D/A - Outlook Therapeutics, Inc. <b>Filed:</b> 2026-08-14 <b>AccNo:</b> 0000899140-26-000895 <b>Size:</b> 15 KB
Read more(99% Neutral) OUTLOOK THERAPEUTICS, INC. (OTLK) Announces Business Combination
Read more(30% Negative) OUTLOOK THERAPEUTICS, INC. (OTLK) Reports Q3 2026 Financial Results
Read moreOutlook Therapeutics Reports Third Quarter Fiscal Year 2026 Financial Results and Provides Business Update Highlighting FDA Approval of LYTENAVA™
Read moreNew Form 424B5 - Outlook Therapeutics, Inc. <b>Filed:</b> 2026-08-14 <b>AccNo:</b> 0001104659-26-096504 <b>Size:</b> 742 KB
Read moreOutlook Therapeutics Announces Pricing of $55.0 Million Public Offering of Common Stock and Warrants
Read more(10% Negative) OUTLOOK THERAPEUTICS, INC. (OTLK) Reports Q3 2026 Financial Results
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT06190093 | A 3-month Study to Assess the Safety and Effectiveness of ONS-5010 in Subjects … | Phase3 | Neovascular Age-related Macular Degeneration | Completed | 2024-01-24 | 2024-12-05 | ClinicalTrials.gov |
| NCT05112861 | A 3-month Study to Compare the Safety of ONS-5010 in Vials Versus Pre-filled Sy… | Phase3 | Age-Related Macular Degeneration | Active_Not_Recruiting | 2021-11-15 | 2027-12-01 | ClinicalTrials.gov |
| NCT04516278 | A 3-month Study to Assess the Safety of ONS-5010 in Subjects With Visual Impair… | Phase3 | Age-related Macular Degeneration | Completed | 2020-10-01 | 2021-02-10 | ClinicalTrials.gov |
| NCT03834753 | A Clinical Effectiveness Study Examining the Efficacy and Safety of ONS-5010 in… | Phase3 | Age-related Macular Degeneration | Completed | 2019-06-25 | 2021-07-08 | ClinicalTrials.gov |
| NCT03844074 | A Clinical Effectiveness Study Examining the Efficacy and Safety of ONS-5010 in… | Phase3 | Age-related Macular Degeneration | Completed | 2018-10-01 | 2020-08-13 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| ranibizumab | Other | Phase PHASE3 | Age-related Macular Degeneration | COMPLETED | NCT03834753 |
| bevacizumab | Other | Phase PHASE3 | Age-related Macular Degeneration | COMPLETED | NCT03834753 |
| ranibizumab | Other | Phase PHASE3 | Neovascular Age-related Macular Degeneration | COMPLETED | NCT06190093 |
| bevacizumab | Other | Phase PHASE3 | Neovascular Age-related Macular Degeneration | COMPLETED | NCT06190093 |
| bevacizumab | Other | Phase PHASE3 | Age-related Macular Degeneration | COMPLETED | NCT04516278 |
| ranibizumab | Other | Phase PHASE3 | Neovascular Age-related Macular Degeneration | COMPLETED | NCT06190093 |
| bevacizumab | Other | Phase PHASE3 | Neovascular Age-related Macular Degeneration | COMPLETED | NCT06190093 |
| bevacizumab | Other | Phase PHASE3 | Age-related Macular Degeneration | COMPLETED | NCT04516278 |
| ranibizumab | Other | Phase PHASE3 | Neovascular Age-related Macular Degeneration | COMPLETED | NCT06190093 |
| bevacizumab | Other | Phase PHASE3 | Neovascular Age-related Macular Degeneration | COMPLETED | NCT06190093 |
| ranibizumab | Other | Phase PHASE3 | Age-related Macular Degeneration | COMPLETED | NCT03844074 |
| bevacizumab | Other | Phase PHASE3 | Age-related Macular Degeneration | COMPLETED | NCT03844074 |
| ranibizumab | Other | Phase PHASE3 | Age-related Macular Degeneration | COMPLETED | NCT03834753 |
| bevacizumab | Other | Phase PHASE3 | Age-related Macular Degeneration | COMPLETED | NCT03834753 |
| bevacizumab | Other | Phase PHASE3 | Age-Related Macular Degeneration | ACTIVE_NOT_RECRUITING | NCT05112861 |
| bevacizumab | Other | Phase PHASE3 | Age-Related Macular Degeneration | ACTIVE_NOT_RECRUITING | NCT05112861 |
| bevacizumab | Other | Phase PHASE3 | Age-Related Macular Degeneration | ACTIVE_NOT_RECRUITING | NCT05112861 |
| bevacizumab | Other | Phase PHASE3 | Age-Related Macular Degeneration | ACTIVE_NOT_RECRUITING | NCT05112861 |
| bevacizumab | Other | Phase PHASE3 | Age-Related Macular Degeneration | ACTIVE_NOT_RECRUITING | NCT05112861 |
| bevacizumab | Other | Phase PHASE3 | Age-Related Macular Degeneration | ACTIVE_NOT_RECRUITING | NCT05112861 |
| bevacizumab | Other | Phase PHASE3 | Age-Related Macular Degeneration | ACTIVE_NOT_RECRUITING | NCT05112861 |
| bevacizumab | Other | Phase PHASE3 | Age-Related Macular Degeneration | ACTIVE_NOT_RECRUITING | NCT05112861 |
| bevacizumab | Other | Phase PHASE3 | Age-Related Macular Degeneration | ACTIVE_NOT_RECRUITING | NCT05112861 |
| ranibizumab | BIOLOGICAL | Phase PHASE3 | Neovascular Age-related Macular Degeneration | COMPLETED | NCT06190093 |
| bevacizumab | BIOLOGICAL | Phase PHASE3 | Neovascular Age-related Macular Degeneration | COMPLETED | NCT06190093 |